Compare Amphastar Pharmaceuticals Inc (AMPH) vs Jones Lang LaSalle Inc (JLL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Jones Lang LaSalle Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $19.44 (market cap $826.08M), while Jones Lang LaSalle Inc trades at $323.88 (market cap $15.05B). The key difference: Jones Lang LaSalle Inc is far larger — about 18.2× Amphastar Pharmaceuticals Inc's market cap, and Jones Lang LaSalle Inc is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | JLL | |
|---|---|---|
Market Cap | $826.08M | $15.05B |
Sector | Health | Real Estate |
52-Week High | $30.81 | $358.66 |
52-Week Low | $16.87 | $248.95 |
Enterprise Value | $1.22B | $18.59B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
JLL trades at $324.44, showing modest daily gains with strong technical momentum and bullish moving averages. The company demonstrates solid fundamental improvement with revenue growth to $26.12B in 2025 and consistent earnings beats. Recent news highlights significant financing deals and Fortune 500 ranking improvement, reflecting strong business execution in commercial real estate services.
JLL presents a compelling investment case with 25% upside to consensus price target of $405.50, supported by improving profitability and positive analyst sentiment. Key risks include commercial real estate market cyclicality and competitive pressures. The stock's current valuation metrics (P/E 17.45, P/S 0.58) appear reasonable given growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Jones Lang LaSalle Inc
Jones Lang LaSalle provides a wide range of real estate-related services to owners, occupiers, and investors worldwide, including leasing, property and project management, and capital markets advisory. JLL's investment management arm, LaSalle Investment Management, manages over $70 billion for clients across diverse public and private real estate strategies.
Read more on JLL →
